Ilomedin (Iloprost Trometamol)

Iloprost trometamol is a prostacyclin analogue that activates prostacyclin (IP) receptors on vascular smooth‑muscle cells. This activation raises cyclic‑AMP levels, causing vasodilation of pulmonary arteries and inhibiting platelet aggregation, which together improve blood flow in the lungs and peripheral tissues.

The dose of Ilomedin is individualized and set by the prescribing physician based on the patient's clinical condition, severity of disease, and response to therapy. Dosing regimens are adjusted during treatment to achieve the desired hemodynamic effect while minimizing adverse reactions.

Safety data for Ilomedin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

Ilomedin belongs to the prostacyclin analogue class, similar to epoprostenol and treprostinil. Compared with epoprostenol, Ilomedin has a longer half‑life, allowing less frequent dosing, and may be associated with a slightly lower incidence of flushing. Choice of agent depends on patient tolerance, delivery system, and physician preference.

Ilomedin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the solution or shake it vigorously. Keep the product in its original packaging until use to maintain stability and sterility.

Ilomedin is administered by intravenous infusion, usually through a central or peripheral line. The infusion rate is titrated by the healthcare professional according to the patient’s hemodynamic response and tolerance, with continuous monitoring of blood pressure and clinical status.

The most serious risks include severe hypotension, which can lead to syncope or organ hypoperfusion, significant bleeding especially when combined with anticoagulants, and pulmonary edema. Patients should be monitored closely for these events, and therapy should be adjusted or discontinued if they occur.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, in those with uncontrolled severe hypotension, and in individuals with active bleeding disorders unless the benefits outweigh the risks. Caution is also advised in patients with severe hepatic or renal impairment.